RxDoctor Payments Data

Deborah Nixon, MD

Dermatology · Charlotte, NCNPI 1073575684

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,584 of the $3,517 with a category attached, or 73.5%. 23 manufacturers reported payments, led by Merck at 31.2% of the total.

$3,517in general payments, 2019–2025

Across 131 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • AbbVie$836
  • Lilly USA, LLC$197
  • Pfizer$149
  • Novartis$134
  • Sanofi$125
  • plus $979 from 17 others
$944,243in research payments, 2019–2025

Across 154 payments — averaging $6131.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sun Pharmaceutical Industries Inc.$336K
  • Eli Lilly$303K
  • Pfizer$156K
  • Amgen$75K
  • Janssen Research & Development, LLC$23K
  • AstraZeneca$23K
  • plus $29K from 3 others

What the payments were for

  • Travel & lodging$85624%
  • Food & beverage$2,58473%
  • Education$772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,517 in reported general payments places this provider in the 60th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$125,927
Medicare patients
379
Services billed
1,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metronidazole33$1,630
Ketoconazole57$1,583
Fluorouracil19$1,051
Fluocinolone Acetonide21$985
ValacyclovirValacyclovir Hcl27$551
Clobetasol Propionate16$505
Fluocinonide19$418
Hydroxychloroquine Sulfate11$389
Doxycycline Monohydrate18$284
Mupirocin43$225
Clindamycin Phosphate14$170
Minoxidil42$156
Triamcinolone Acetonide15$122

Paid to pharmacies, not to this prescriber.

Other dermatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →